• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
149391 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
8 o' r  B2 H- b+ F' P
2 }. ]$ f$ s6 }+ e! l( I* l3 _3 [7 ^) m3 [% o% [
Sub-category:  w" \6 b1 ]: H
Molecular Targets
% a( l& n0 p1 V0 e8 G1 V1 f$ F" c
2 f4 a# V" c. z- N& E, h3 [( I( Y1 P6 ^5 X0 I/ n( L8 [
Category:
5 V! q9 f% H1 o+ LTumor Biology 2 z0 M# W* l- X" b1 |0 ?0 X
# [+ ^) t9 c) X' Q  P9 }
8 k3 s; A% B* a
Meeting:
3 r; o' h8 _" ~2011 ASCO Annual Meeting ( y' U4 u( S( s- @% q1 Y

* y. }# \% K2 M: i' l: v  y( R
# _; U+ A$ r$ u& ]  q. m" mSession Type and Session Title:" c- }1 _* g4 J' t
Poster Discussion Session, Tumor Biology + _# }4 _9 _; T- K: v" t+ R
0 g0 j3 S5 v  e/ g: o, X

9 A+ h2 Q+ h' F6 A5 J- i6 iAbstract No:
7 s2 Z: m3 Y- p: k0 l; g9 I8 P( e" z7 `10517 ! l# q' d( R9 X( @8 \
9 @1 _& t1 T9 a2 i- [

$ c/ a! x' T/ A' L) }; e5 sCitation:
' Z7 i1 h- G7 I4 N3 P! @5 eJ Clin Oncol 29: 2011 (suppl; abstr 10517) 9 f  k9 N, L+ T; m  I

) D+ ^+ f3 m6 s) c) ]5 l
0 `, N- ]* K! g; `+ ]# h. qAuthor(s):
0 n% i" s% b9 v  ~3 L2 U( N; XJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
8 B, o9 g/ i" z* V+ u! G; c
3 U9 }* v* Y. H# U& H; k7 |
$ o$ x% d0 L/ z1 N/ Y3 K/ ^: x' J0 f; d- b
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.2 N! F. S, n9 N; W

. {+ F6 N5 R5 j8 l5 ]2 HAbstract Disclosures
: {. P( Z4 z* ^! L; I
- }2 ~  l$ S% z8 {! ]: b: gAbstract:
! a) H$ P( H0 H0 @4 o3 m6 W9 D
( c' x/ a1 P' ?7 m* Z7 }1 w- @$ @$ {
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.+ l  X* @2 L) f2 U8 J( f
( w; h# L3 |: L* `- v0 h
% Q7 w( s' ~! b+ [5 F/ U$ P& H. R
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 6 \" ^1 W* ^* r
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

* w2 N7 W% j4 Y9 p5 z化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 9 o8 E! C3 H: h! J; M. x$ l, n
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。$ c# U" @: S3 Y! w
ALK一个指标医院要900多 ...
* a6 z5 X- E8 u4 S5 L+ \
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?9 H1 V$ D1 ^/ U) b" C! {- U
. t. ]& c& j7 @; b% u6 N+ F: @
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表